Talphera, Inc. (TLPH)
| Market Cap | 41.72M +297.4% |
| Revenue (ttm) | 1,000 -96.3% |
| Net Income | -14.25M |
| EPS | -0.27 |
| Shares Out | 51.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,921 |
| Open | 0.8030 |
| Previous Close | 0.8160 |
| Day's Range | 0.7925 - 0.8149 |
| 52-Week Range | 0.3800 - 1.5700 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 3.25 (+304.28%) |
| Earnings Date | May 13, 2026 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Feds... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TLPH stock is "Buy." The 12-month stock price target is $3.25, which is an increase of 304.28% from the latest price.
News
Talphera reports Q1 EPS (4c) vs. (10c) last year
Cash and investments balance was $21.1M as of March 31. “In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady…
Talphera Earnings Call Transcript: Q1 2026
Enrollment in the NEPHRO study surpassed 50%, with completion and top-line data expected in the second half of 2026. Cash balance stands at $21.1 million, with additional financing tranches anticipated to fund operations through potential Niyad approval.
Talphera Earnings release: Q1 2026
Talphera released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Talphera Quarterly report: Q1 2026
Talphera has published its Q1 2026 quarterly earnings report on May 13, 2026.
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SA...
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Talphera initiated with a Buy at WestPark Capital
WestPark Capital analyst Ed Arce initiated coverage of Talphera (TLPH) with a Buy rating and $3 price target The firm says the company is brining the best continuous renal replacement…
Talphera Proxy statement: Proxy filing
Talphera filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Talphera Proxy statement: Proxy filing
Talphera filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Talphera Slides: Corporate presentation
Talphera has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera Registration statement: Registration filing
Talphera filed a registration statement on March 25, 2026, providing details about a securities offering with the SEC.
Talphera files to sell 639,931 shares of common stock for holders
06:03 EDT Talphera (TLPH) files to sell 639,931 shares of common stock for holders
Talphera Earnings Call Transcript: Q4 2025
The Nephro CRRT study reached 50% enrollment, unlocking $4.1M in financing and progressing toward FDA approval for Niyad. Experts highlight significant operational and safety limitations with current CRRT anticoagulants, anticipating that Niyad could become the preferred option due to its simplicity and effectiveness.
Talphera Annual report: Q4 2025
Talphera has published its Q4 2025 annual report on March 23, 2026.
Talphera Earnings release: Q4 2025
Talphera released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Talphera reports Q4 EPS (6c) vs. (7c) last year
Reports cash and investments of $20.4M at December 31, 2025. “Earlier this month, we communicated reaching the 35-patient enrollment mark in the 70-patient nafamostat registrational study for CRRT. Si...
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to e...
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera announces 50% patient enrollment of the NEPHRO-CRRT clinical trial
Talphera (TLPH) announced 50% patient enrollment of the NEPHRO-CRRT clinical trial. “Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinica...
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET fe...
Talphera Earnings Call Transcript: Q3 2025
NEPHRO study enrollment accelerated after protocol changes, but delays in activating new high-volume sites have shifted expected completion to H1 2026. Cash position and recent financing provide runway through anticipated Niyad PMA approval, with operating expenses reduced year-over-year.
Talphera Quarterly report: Q3 2025
Talphera has published its Q3 2025 quarterly earnings report on November 12, 2025.
Talphera Earnings release: Q3 2025
Talphera released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Talphera reports Q3 EPS (11c) vs. (13c) last year
Reports Q3 revenue $1K vs. $0 last year. “The financing closed in September, led by a strategic investment from CorMedix, combined with future conditional tranches, is expected to provide us…